MARKET

DVAX

DVAX

Dynavax Techs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.05
+0.16
+1.07%
Opening 10:56 09/20 EDT
OPEN
14.38
PREV CLOSE
14.89
HIGH
15.05
LOW
14.29
VOLUME
755.73K
TURNOVER
--
52 WEEK HIGH
20.40
52 WEEK LOW
3.580
MARKET CAP
1.73B
P/E (TTM)
-271.1712
1D
5D
1M
3M
1Y
5Y
12 Best Meme Stocks to Invest In
In this article, we discuss the 12 best meme stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Meme Stocks to Invest In. Retail trading has increased dramatically as a result of zero-commission online...
Insider Monkey · 3d ago
Breakeven Is Near for Dynavax Technologies Corporation (NASDAQ:DVAX)
Dynavax Technologies Corporation ( NASDAQ:DVAX ) is possibly approaching a major achievement in its business, so we...
Simply Wall St. · 5d ago
Top Pharmaceutical Stocks for Q4 2021
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2021.
Investopedia · 5d ago
UPDATE 1-UK would not have approved Valneva COVID vaccine, health secretary says
reuters.com · 6d ago
72 Biggest Movers From Yesterday
Gainers
Benzinga · 6d ago
Cramer's lightning round: 'Go buy some Ethereum' instead of Hut 8 Mining
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC.com · 6d ago
Itamar Medical, aTyr Pharma leads healthcare gainers; MiMedx, Silverback Therapeutics among major losers
Gainers: Itamar Medical (NASDAQ:ITMR) +45%, aTyr Pharma (NASDAQ:LIFE) +35%, iRhythm Technologies (NASDAQ:IRTC) +33%, REGENXBIO (NASDAQ:RGNX) +20%, Leap Therapeutics (NASDAQ:LPTX) +15%. Losers: MiMedx (NASDAQ:MDXG) -61%, Silverback Therapeutics (NASDAQ:SBTX...
Seekingalpha · 6d ago
Why Dynavax Shares Are Trading Lower Today
Dynavax Technologies Corp (NASDAQ: DVAX) is trading lower after the company announced Valneva SE (NASDAQ: VALN) received a termination notice from the United Kingdom government in relation to Valneva's supply a
Benzinga · 09/13 14:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DVAX. Analyze the recent business situations of Dynavax Techs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DVAX stock price target is 20.50 with a high estimate of 23.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 230
Institutional Holdings: 107.62M
% Owned: 93.78%
Shares Outstanding: 114.76M
TypeInstitutionsShares
Increased
54
7.88M
New
16
3.82M
Decreased
45
3.81M
Sold Out
23
1.90M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.50%
Pharmaceuticals & Medical Research
-0.51%
Key Executives
Non-Executive Chairman/Independent Director
Andrew Hack
President/Chief Operating Officer
David Novack
Chief Executive Officer/Director
Ryan Spencer
Chief Financial Officer/Senior Vice President
Kelly MacDonald
Senior Vice President/General Counsel
John Slebir
Senior Vice President/Director of Human Resources
Jeff Coon
Senior Vice President
Robert Janssen
Senior Vice President
Dong Yu
Independent Director
Francis Cano
Independent Director
Julie Eastland
Independent Director
Daniel Kisner
Independent Director
Brent MacGregor
Independent Director
Peter Paradiso
Independent Director
Peggy Phillips
Independent Director
Natale Ricciardi
No Data
About DVAX
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Webull offers kinds of Dynavax Technologies Corporation stock information, including NASDAQ:DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DVAX stock methods without spending real money on the virtual paper trading platform.